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Complications involving the central nervous system (CNS) occur in 9–14% of patients
following allogeneic hematopoietic stem cell transplantation (HSCT), including stroke-like
episodes, demyelination, encephalitis, and nonspecific neurological symptoms. Here
we report a case of multiple sclerosis (MS) like relapsing remitting encephalomyelitis
following allogeneic HSCT, which did not respond to disease modifying therapies
(DMTs) and “domino” autologous HSCT. A 53-year-old male was treated with allogeneic
HSCT for lymphoid blast transformation of chronic myeloid leukemia. Ten months later
he presented with confusion, slurred speech, left sided facial weakness and ataxia.
A magnetic resonance imaging brain scan showed multiple enhancing tumefactive
lesions. Neuromyelitis optica (NMO) and myelin oligodendrocyte glycoprotein (MOG)
antibodies were negative. After extensive investigations for infections, autoimmune
disorders and recurrence of malignancy, he underwent brain biopsy, which showed
a macrophage rich lesion with severe myelin loss but axonal preservation indicating
a demyelinating pathology. Although his symptoms improved with corticosteroids, he
relapsed five months later. In the absence of any systemic features suggesting graft
versus host disease (GvHD), his presentation was thought to be compatible with MS.
The illness followed an aggressive course that did not respond to glatiramer acetate
and natalizumab. He was therefore treated with “domino” autologous HSCT, which
also failed to induce long-term remission. Despite further treatment with ocrelizumab,
he died of progressive disease. An autopsy limited to the examination of brain
revealed multifocal destructive leukoencephalopathy with severe myelin and axonal loss.
Immunohistochemistry showed macrophage located in the perivascular area, with no T
or B lymphocytes. The appearance was unusual and not typical for chronic MS plaques.
Reported cases of CNS demyelination following allogeneic HSCT are very limited in the
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literature, especially in relation to histopathological examination. Although the clinical
disease course of our patient following allogeneic HSCT resembled an “MS-like” relapsing
remitting encephalomyelitis, the autopsy examination did not show any evidence of active
inflammation. The impact of DMTs and HSCT on the histological appearance of “MS-like”
CNS pathologies is unknown. Therefore, reporting this and similar cases will improve our
awareness and understanding of underlying disease mechanisms.
Keywords: multiple sclerosis, allogeneic hematopoietic stem cell transplantation, “domino” autologous
hematopoietic stem cell transplantation, graft versus host disease, multifocal leukoencephalopathy
INTRODUCTION
Complications involving the central nervous system (CNS) occur
in 9–14% of patients following allogeneic hematopoietic stem
cell transplantation (HSCT) (1). These include drug toxicities,
infections, and metabolic disturbances (2, 3). Graft versus host
disease (GvHD) associated with allogeneic HSCT usually affects
skin, gut, and liver. GvHD rarely affects the CNS, but when it is
involved there is often a significant systemic GvHD elsewhere (4).
Patients with chronic GvHD affecting the CNS may present with
stroke-like episodes, transverse myelitis, multiple sclerosis (MS)
or acute disseminated encephalomyelitis (ADEM) like disorders,
encephalitis, and other nonspecific neurological symptoms (5).
Secondary autoimmune diseases, particularly thyroid
and other endocrine disorders are recognized complications
following allogeneic HSCT, but MS-like presentation has rarely
been reported in the literature (5–8). In some cases, there is
apparent adoptive transfer of specific autoimmune diseases or
autoimmune diathesis (9). Here we report a case of “MS-like”
relapsing remitting encephalomyelitis following allogeneic
HSCT, which did not respond to three disease modifying
therapies (DMTs) and “domino” autologous HSCT.
CASE PRESENTATION
A 53-year-old male with chronic myeloid leukemia (CML),
who failed to respond to imatinib (tyrosine kinase inhibitor),
underwent allogeneic HSCT for lymphoid blast transformation
eighteen months after his initial presentation. Following
lymphoid blast transformation, imatinib was also switched
to nilotinib (tyrosine kinase inhibitor). The allogeneic HSCT
was performed using a conditioning regimen consisting of
fludarabine, busulphan and anti-thymocyte globulin (ATG)
with ciclosporin A as GvHD prophylaxis. An unrelated male
donor matched for HLA A, B, C, and DR loci was used
(Supplementary Table 1). Neither donor nor patient had the
HLA-DRB1∗15:01 genotype associated with increased risk of
MS (10). Engraftment of neutrophils and platelets occurred
promptly, but the patient had routine transplant related
toxicities, including post-transplant cytomegalovirus (CMV)
reactivation and possible posterior reversible encephalopathy
syndrome for which GvHD prophylaxis was switched from
ciclosporin A to tacrolimus. There were no changes suggestive
of demyelination on brain magnetic resonance imaging (MRI).
Tacrolimus was successfully weaned off without GvHD. In
view of the high relapse risk, he was maintained on nilotinib
post-transplant. Subsequent bone marrow examinations along
with peripheral blood monitoring showed full donor chimerism
and molecular negativity for BCR-ABL transcripts confirming
ongoing molecular remission of leukemia consistent with cure.
Despite a good initial recovery, 10 months later the patient
was admitted with confusion, slurred speech, left sided facial
weakness, and ataxia (Figure 1A). He had no systemic features
suggestive of GvHD, such as rash, deranged liver function,
or gastrointestinal disturbance. A brain MRI showed contrast
enhancing tumefactive lesions in the left peri-insular area, both
corona radiatae and brainstem (Figures 1B,C). Screenings for
human immunodeficiency virus (HIV), Borrelia burgdorferi,
syphilis and toxoplasmosis in serum were negative. Analysis of
the cerebrospinal fluid (CSF) showed a white cell count of 3 ×
106 /L with marginally elevated protein of 0.76 g/L and normal
CSF to serum glucose ratio. He had matching bands in CSF and
serum (type 4). Screenings for herpes simplex virus (type 1, 2, 6,
and 7), varicella zoster virus, adenovirus, enteroviruses, Epstein-
Barr virus (EBV), CMV and John Cunningham (JC) virus in
CSF were negative. Immunophenotyping of CSF cells and a
computed tomography (CT) scan of thorax, abdomen and pelvis
did not detect any new or recurrent malignancy. Autoantibody
screening for connective tissue diseases and systemic vasculitis
were negative.
The patient underwent a brain biopsy, which showed
a heavy infiltration of macrophages (CD68-positive), with
isolated T (CD3-positive), and B (CD79a-positive) lymphocytes.
A luxol fast blue stain revealed severe myelin loss whilst
immunohistochemistry to neurofilament protein revealed
preserved axons, although some were showing damage and
swellings. Reactive astrocytes were present. There was no frank
necrosis. Apoptotic cells were not conspicuous and there was
no neoplastic infiltration. Special stains for bacteria and fungi
were negative, as was immunohistochemistry for JC virus (SV40
antigen). The biopsy findings of a macrophage rich lesion with
severe myelin loss but relative axonal preservation suggested a
demyelinating pathology (Figure 2). Culture, 16s rRNA gene
detection test, screening for pan-fungal and Aspergillus sp. were
negative in the biopsy sample.
In the absence of systemic features suggesting GvHD,
infections and relapse of CML, his clinical presentation and
investigation results were considered to be in keeping with
possible ADEM. He was treated with a 3-day course of
intravenous methylprednisolone followed by tapering doses
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FIGURE 1 | (A) A summary of the disease course. (B) Axial sections of the brain MRI showed tumefactive lesions. (C) Improvement of the edema around tumefactive
lesions. (D) The spine MRI demonstrated a lesion extending from the thoracic cord to conus.
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FIGURE 2 | Brain biopsy neuropathology. (A) Biopsy appeared hypercellular, with a dense macrophage infiltrate. (B) Infiltrating population was confirmed as
macrophages by immunohistochemistry to CD68. (C) Luxol fast blue stain demonstrating virtually total myelin loss. (D) Immunohistochemistry demonstrated relative
preservation of axons; these were separated by infiltrating macrophages, and show irregularity, representing damage. (E) Immunohistochemistry to GFAP showing
reactive astrocytes. (F) Immunohistochemistry to CD3 demonstrated sparse T cells (arrow). (G) A few CD79a-positive B cells were also present. Magnifications as
shown on scale bars.
of oral prednisolone. His neurological symptoms gradually
resolved, and he was walking 3−5 miles daily without assistance.
Six months later, he was re-admitted with a 3-week history of
paraesthesia and weakness of lower limbs and urinary retention.
A brain MRI revealed a new enhancing lesion in the occipital
horn adjacent to the left lateral ventricle and a spine MRI showed
a contrast enhancing lesion in the thoracic cord extending to the
conus (Figure 1D). Similar to previous lumbar puncture results,
CSF analysis showed mildly elevated protein with matching
bands in CSF and serum. Neuromyelitis optica (NMO) antibody
in serum was negative. He was treated with another course
of intravenous methylprednisolone and a tapering dose of oral
prednisolone. He made a full recovery within several weeks
and continued to walk 3–5 miles a day. An enquiry to the
donor registry confirmed that the donor remained fit and healthy
without neurological or autoimmune diseases.
This case therefore posed a unique diagnostic challenge of
differentiating between CNS demyelinating disorders and “pure”
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CNS GvHD. This presentation neither fulfilled the international
consensus diagnostic criteria for NMO spectrum disorder nor
the Grauer et al. criteria for the CNS manifestations of GvHD
due to the lack of systemic involvement (4, 11). The relapsing
remitting disease course was unlikely to be caused by fludarabine
or nilotinib toxicity. As the clinical and radiological presentations
together with brain biopsy results were thought to be more
compatible with relapsing remitting MS, he was commenced
on glatiramer acetate and continued on oral prednisolone 5
mg daily.
Two months later, he had another episode of severe
myelitis, which was treated with a further course of intravenous
methylprednisolone. As the CSF was negative for JC virus,
glatiramer acetate was switched to natalizumab, but his disability
did not improve and his expanded disability status scale (EDSS)
score remained 8.0.
The patient continued to deteriorate requiring another
admission with left sided facial and arm weakness five months
after starting natalizumab. In view of the diagnostic uncertainty
the patient was continued to be investigated for an alternative
diagnosis. A spine MRI showed an enhancing lesion in the
cervical cord. A third lumbar puncture did not show any new
changes and JC virus in CSF remained negative. He was treated
with another course of intravenous methylprednisolone. Over
the ensuing 15 months, serial MRI scans identified multiple new
enhancing lesions in the brain and spinal cord. Visual evoked
potentials did not show any evidence of optic nerve involvement
on two separate occasions. NMO and myelin oligodendrocyte
glycoprotein (MOG) antibodies in serum remained negative.
As he had highly active disease clinically and radiologically
despite treatment with a high efficacy DMT, autologous HSCT
was considered. As his hematopoietic system was entirely derived
from the matched unrelated donor used for the allogeneic
HSCT, this was a “domino” autologous HSCT where the
patient, a recipient of the previous allogeneic transplant, served
as a “donor” for his second transplant. Natalizumab was
discontinued and his peripheral blood hematopoietic stem cells
were mobilized with cyclophosphamide 2 g/m2 and granulocyte-
colony stimulating factor. This admission was complicated
by confusion secondary to hyponatremia and a urinary tract
infection from which he fully recovered.
A cautious approach was adopted, with a decision to observe
the neurological response following cyclophosphamide-primed
stem cells mobilization, before pursuing with the “domino”
autologous HSCT. However, the patient was re-admitted with
dysarthria and dysphagia three months later and a brain MRI
showed four new enhancing lesions. A decision was therefore
made to proceed with the “domino” autologous HSCT following
immunoablation with cyclophosphamide and ATG. Similar to
the first transplant, the engraftment of neutrophils and platelets
occurred promptly. He had routine transplant related toxicities
and also made an unhindered recovery following discharge from
hospital. Nilotinib was discontinued after the transplant. Three
months later his EDSS score was 7.0.
Twelve months after the transplant, he was admitted with
confusion, swallowing difficulties and aspiration pneumonia. A
brain MRI revealed new enhancing lesions in the left occipital
lobe. He was re-investigated for opportunistic infections and
malignancies. Sputum culture, throat swabs, galactomannan, and
β-d-glucan tests, multiple blood cultures and viral screenings for
HIV, hepatitis B and C, syphilis, toxoplasmosis and cryptococcus
were negative. Autoimmune screening for connective tissue
disease and vasculitis were also negative. A lumbar puncture
showed CSF protein of 0.99 g/L and white cell count of 56
× 106 /L with lymphocytosis. CSF to serum glucose ratio
was normal. CSF culture and screening for JC virus, EBV,
CMV, toxoplasmosis, Cryptococcus, and acid-fast bacilli were
negative. On this occasion, there were matching bands in
serum and CSF as well as additional monoclonal bands. Neither
immunophenotyping of cells in CSF nor CT scan of chest,
abdomen and pelvis showed any evidence of recurrence or new
malignancy. A second brain biopsy was offered but declined by
the patient.
Over the next ten months, he had several brain and spine
MRIs, which continued to show radiologically active disease with
new T2 lesions and contrast enhancements. He continued oral
prednisolone 5mg daily. He was started on ocrelizumab but died
of progressive disease four months later.
The patient underwent a post-mortem limited to the
examination of the brain which weighed 1,208 g and was
examined after fixation. Coronal slices of the brain revealed
multifocal, irregular white matter lesions in frontal, temporal,
and occipital lobes, measuring up to 30mm in diameter. The
lesions had a yellowish granular appearance with a tendency to
cavitation. Subcortical arcuate (U-) fibers were not spared. These
lesions did not have the appearance of classical MS plaques.
In places lesions were sharply circumscribed but elsewhere
had more diffuse margins. Myelin stains demonstrated virtually
total myelin loss and neurofilament immunohistochemistry
showed severe axonal loss with a few remained axonal
threads at the lesion margins in contrast to the biopsy. Beta
amyloid precursor proteins was upregulated in axons and
pyramidal cells at the lesion margins. Ameboid macrophages
were highlighted by CD68, particularly in a perivascular
location but immunohistochemistry to CD3 and CD20 did
not reveal T or B cell infiltration. Occasional vessels showed
perivascular sclerosis, but immunohistochemistry to smooth
muscle actin showed preservation of vascular media suggesting
that there was not a vasculopathy process. S100 labeled small
round nuclei in the lesions, suggesting some preservation of
oligodendrocytes. No oligodendroglial inclusions were seen and
immunohistochemistry for JC virus (SV40 antigen) was negative,
as were stains for bacteria and fungi. Focal brown pigment
was present, staining with both the Perl’s and Masson Fontana
methods, suggesting that haemosiderin and some melanin was
present. The findings were of a multifocal leukoencephalopathy,
with severe loss of both axons and myelin (Figure 3).
DISCUSSION
This is an unusual case of MS-like relapsing remitting
encephalomyelitis following allogeneic HSCT, which did not
respond to DMTs and “domino” autologous HSCT. This
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FIGURE 3 | Post-mortem neuropathology. (A) Coronal slice of cerebrum showing three irregular, cavitating white matter lesions (arrows). There is some dilatation ex
vacuo of the ventricles, presumably secondary to white matter loss. (B) H and E stained section showing part of a lesion with preserved cortex above (star). (C) Luxol
fast blue showing loss of myelin. (D) High power view of lesion stained with luxol fast blue shows total loss of myelin. (E) Neurofilament immunohistochemistry
showing total axon loss in the center of a lesion. (F) Toward the lesion margin a few axons remain (arrows). (G) Up-regulation of amyloid precursor protein, upper left,
with multiple axonal spheroids (arrow). (H) CD68 staining showing ameboid microglia, particularly in a perivascular location. Magnifications as shown on scale bars.
patient’s disease course run an initial relapsing remitting phase
with complete neurological recovery which was followed by
a progressive disease phase with superimposed acute episodic
neurological dysfunction. There were correspondingMRI disease
activities in brain and spine throughout the disease course.
The initial brain biopsy showed a macrophage rich lesion
with loss of myelin, but relative preservation of axons, which
would be consistent with a demyelinating pathology. It is a
rare histological feature of hematological neoplasm and may
be erroneously diagnosed as inflammatory demyelination if
corticosteroid therapy is used prior to the brain biopsy (20).
Acute plaques of demyelination usually have T cells, which
tend to be localized perivascularly and are less prevalent
than macrophages (21). In tumefactive MS, T cells are
detected at lower levels than in biopsies that subsequently
turn out to be lymphoma (20). However in a small biopsy
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TABLE 1 | Demographic details, allogeneic HSCT procedures, GvHD and other immune mediated complications of post-transplant CNS demyelinating disorders.
No Age of
HSCT
Gender Initial disease Donor Conditioning
regimen
GvHD
prophylaxis
GvHD history Peripheral nerve
involvement
References
1 24 Male Lymphoblastic T
cells lymphoma
HLA (B, C DR identical
and A mismatched)
mixed lymphocytic
culture non-reactive
mother
NA NA Liver and
cutaneous
Yes (12)
2 32 Female MDS Matched related donor Bu and Cy CsA and
Methotrexate
Liver and
Cutaneous*
NA (13)
3 58 Male CMML Unrelated donor Bu and Flu ATG,
Methotrexate,
and Tacrolimus
No NA (6)
4 65 Male AML Matched related donor TBI, Cy Flu,
Amsacrine,
Cytarabine, and
ATG
CsA and MMF No NA (6)
5 50 Male Myeloproliferative
neoplasms
Matched related donor Myeloablative
regimen
CsA and MMF Muscle NA (5)
6 36 Male ALL Matched related donor NA CsA and
Tacrolimus
Gut NA (7)
7 35 Female MDS Matched unrelated
donor
Bu, Flu, and ATG Methotrexate Cutaneous and
liver
NA (14)
8 41 Male Aplastic anemia Matched unrelated
donor
TBI, Cy, and ATG CsA and
Corticosteroids
Lung, muscle,
and cutaneous*
NA (15)
9 59 Male AML Matched related donor TBI, Cy, Flu,
Cytarabine, and
GCSF
ATG, CsA, and
MMF
Cutaneous Yes (8)
10 55 Male AML Matched unrelated
donor
NA NA No Yes (8)
11 53 Male AML Matched related donor TBI, Cy, Flu,
Cytarabine, and
Amsacrine
ATG, MMF, and
Tacrolimus
No Yes (8)
12 56 Male CMML Matched unrelated
donor
Bu and Flu ATG,
Methotrexate,
and Tacrolimus
No Yes (8)
13 53 Female CML Matched related donor NA NA No Yes (8)
14 33 Male Hodgkin
lymphoma
Matched unrelated
donor
Flu and
Melphalan
ATG, MMF, and
Tacrolimus
Cutaneous and
muscle
Yes (8)
15 54 Male AML Matched related donor NA NA No NA (16)
16 59 Male AML Matched related donor NA NA No NA (16)
17 29 Female AML Matched related donor NA NA Cutaneous NA (16)
18 40 Male CML blast crisis NA Bu and Cy CsA and
Corticosteroids
Cutaneous NA (17)
19 36 Female MDS Matched unrelated
donor
Bu and Cy CsA and
methotrexate
Possible
cutaneous*
NA (18)
20 17 Male AML Matched related donor NA CsA and
Corticosteroids
No NA (19)
*Patient also had cytopenia.
ALL, Acute lymphoblastic leukemia; AML, Acute myeloid leukemia; ATG, Anti-thymocyte globulin; Bu, Busulfan; CML, Chronic myeloid leukemia; CMML, Chronic myelomonocytic
leukemia; Cy, Cyclophosphamide; Cyclosporin-A, CsA; Flu, Fludarabine; GCSF, Granulocyte colony stimulating factor; HSCT, Hematopoietic stem cell transplantation; GvHD, Graft
versus host disease; MDS, Myelodysplastic syndrome; MMF, Mycophenolate mofetil; NA, Not available; and TBI, Total body irradiation.
sample, it is possible that these changes may not be well
represented, which is a ubiquitous problem independent of
disease studied (21). In the absence of clinical features
suggestive of GvHD and CML recurrence, his brain biopsy
was thought to be consistent with a primary inflammatory
demyelinating plaque.
The use of fludarabine has previously been associated
with monophasic diffuse necrotizing leukoencephalopathy (22).
Although five cases of CNS demyelination had also been reported
in patients receiving treatment with nilotinib or imatinib for
various malignancies, it was not clear if tyrosine kinase inhibitors
were the causal agents, particularly as two out of those five
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TABLE 2 | Clinical features, investigation results and treatment outcomes of post-transplant CNS demyelinating disorders.
No Clinical
syndrome
HSCT to
onset
(year)
Location of MRI lesions CSF Biopsy Clinical
course
Follow up
period (year)
Treatment Treatment
response
Residual disabilities
1 MS-like 1 Brainstem, cerebellum, and
corona radiata
OCB (Type 4) and
lymphocytosis
No Relapsing
remitting
2.3 Corticosteroids
and TPE
Marginal
improvement
Wheelchair bound
2 ON with
myelitis
0.6 Internal capsule, thalamus,
and cervical cord with Gd-
enhancement
Normal No Relapsing
remitting
1 Corticosteroids
and Cs A
Partial
improvement
Had residual deficits
3 Myelitis 0.1 Cervical and thoracic cord Raised protein No Relapsing
remitting
4.5 Corticosteroids,
CsA, and Cy
Partial
improvement
Was able to walk 500 m
4 MS-like 3 Left hemisphere, cervical, and
thoracic spine with
Gd-enhancement
Raised protein and
OCB
No Relapsing
remitting
3 Corticosteroids Complete
resolution
Nil
5 MS-like 7 Compatible with MS Normal No NA 8.3 Cs A Complete
resolution
Nil
6** MS 2 Corpus callosum, right
temporal subcortex, cervical,
and thoracic cord with
Gd-enhancement
Normal Brain
biopsy—complete loss
of myelin compatible
with MS
Relapsing
remitting
3 Corticosteroids
and Interferon β
Complete
resolution
Nil
7** ADEM 2 Fontal subcortex,
periventricular area, occipital
lobe, and thoracic cord
Normal Brain biopsy—loss of
myelin thought to be
GvHD and spine biopsy
showed fibrosis
Single episode 1 Corticosteroids,
TPE, and
Tacrolimus
Complete
resolution
Nil
8 Myelitis 0.5 Cervical and thoracic cord Raised protein No One episode
and a possible
relapse
3 Corticosteroids Complete
resolution
Nil
9** ON with
myelitis
8 Bilateral pre- and
post-chiasm, cervical, and
thoracic cord and meningeal
enhancement, cervical
Pleocytosis with
OCB (type 2)
No NA NA Corticosteroids,
IVIG, Rituximab
Marginal
improvement
Unable to stand up or
walk
10** MS 2.6 Brainstem and periventricular
lesions
Raised protein
with OCB (type 2)
NA NA NA Corticosteroids,
Interferon β,
Rituximab
Marginal
improvement
Spastic quadriparesis and
gait instability
11** NMOSD 1 Left pre-chiasmatic lesions
and LETM in thoracic and
lumbar cord
Raised protein,
and pleocytosis
No NA NA Corticosteroids,
TPE, Rituximab
Marginal
improvement
Visual impairment and
spastic paraparesis
12 Myelitis 0.25 Cervical and thoracic spine NA No NA NA Corticosteroids
and Cy
Marginal
improvement
Spastic quadriparesis and
gait Instability
13** Myelitis 5 Spinal cord WM and cerebral
peduncles
Normal No NA NA Corticosteroids No improvement Left sided spastic
hemiparesis, gait
instability, and sensory
deficits
14** ON with
myelitis
0.33 Periventricular lesions, optic
nerve atrophy, and spinal cord
WM
Raised protein,
and pleocytosis
Sural nerve
biopsy—demyelination
and axonal
degeneration
NA NA Corticosteroids,
TPE, IVIG, and
Rituximab
Marginal
improvement
Spastic quadriparesis,
visual impairment, and
gait instability
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patients recovered without discontinuing these drugs (23–25).
Furthermore, tyrosine kinase inhibitor had therapeutic benefit
in people with progressive forms of MS and drug toxicities are
unlikely to present with a relapsing remitting disease course (26).
There was further discordance between the clinical
presentation and the autopsy findings, which showed a
destructive leukoencephalopathy. Although the initial biopsy
showed demyelination, lymphocytic infiltration was not a
feature of either the biopsy or the white matter lesions at
autopsy. It is not known how DMTs and HSCT modulate the
histological appearance of CNS demyelination. Although the
innate immune system recovers within weeks after HSCT, the
reconstitution of adoptive immune system occurs over several
years. Immunohistochemistry to CD3 and CD20 did not show
any T or B cell infiltration during autopsy examination. In
particular, ATG was used for in vivo T cell purging during
domino autologous HSCT. Furthermore, the patient received
two doses of ocrelizumab prior to his death. This humanized
anti-CD20 monoclonal antibody targets B lymphocytes. The
lack of inflammatory cells in the autopsy histology samples
could be related to primary underlying pathology or the effect of
ocrelizumab and / or the HSCT received earlier.
To our knowledge this was the first patient with MS-like
neuroinflammation following allogeneic HSCT, who was treated
with a “domino” autologous HSCT. Our patient experienced
an aggressive disease course and rapidly became disabled.
His failure to respond to glatiramer acetate and natalizumab
left his neurologists with limited treatment options. Although
the use of alemtuzumab was not completely contraindicated,
caution was exercised, as it could cause a prolonged period
of lymphopenia potentially making it a less appropriate choice
given his immunosuppressed state following allogeneic HSCT
(27). Autologous HSCT has been increasingly used to treat
patients with MS, who have highly active disease clinically
and radiologically, as the safety and efficacy of this procedure
has increased over the years through improvement of patient
selection, optimization of transplant technique and increased
center experience (28). This was therefore thought to be the
best treatment option. Although the procedure was associated
with routine and well-tolerated toxicities, the response was only
transient and failed to achieve long-term remission. In this case,
we chose a clinical decision pathway directed at MS, with the use
of three DMTs and HSCT, whereas the management of chronic
GvHD would have been significantly different. Calcineurin
inhibitors, higher doses of steroids, mycophenolate and even
extracorporeal photopheresis could have been used for GvHD.
We can only speculate whether GvHD management would have
made a greater impact on the course of his CNS inflammation
compared with a DMT-based, MS-directed approach, even
though systemic GvHD was not present.
Reported cases of CNS demyelinating disorders following
allogeneic HSCT are very limited. Tables 1, 2 summarize 20 such
cases that have been reported in the literature (5–8, 12–19).
The median age of receiving allogeneic HSCT was 45.5 (range,
17–65) years and the median interval between HSCT and the
onset of CNS demyelination was 1 (range, 0.1–8) year. Twelve
of these patients presented with neurological symptoms within 1
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year of allogeneic HSCT and remaining eight patients developed
neurological symptoms after 2 years or more. Male to female
ratio was 3: 1. There was evidence of GvHD in 12 patients
and peripheral nerves involvement was reported in 13 patients.
Inflammation less frequently affected brainstem, cerebellum and
meninges. CSF analysis was normal in only 6 patients and
oligoclonal bands were present in 7 patients.
The clinical course of these patients was monophasic or
relapsing remitting. They had variable clinical presentations
including optic neuritis with myelitis, pure myelitis, ADEM, and
MS-like neuroinflammation (Table 2). The diagnostic criteria
for MS and NMO spectrum disorder were satisfied in two
patients each. NMO antibody was absent in all cases where
it was examined (Table 2). Terminologies such as “central
and peripheral nervous system immune-mediated demyelinating
disease (CPID)” and “immune-mediated demyelinating disease
(IMDD)” had been coined by some authors to refer these
presentations as a rare late onset complication of allogeneic
HSCT (8, 16). Some authors also suggested that these
presentations may be CNS manifestation of GvHD (5). Three
patients had brain biopsy, two had spine biopsy and another
person had sural nerve biopsy. All of these biopsies showed loss
of myelin and the brain biopsy of one patient was compatible
with GvHD (Table 2). None of those case reports included post-
mortem examination.
One possible pathophysiological mechanism of CNS
demyelination following allogeneic HSCT could be immune
mediated damage due to minor histocompatibility differences
between brain tissues and the graft derived cells. Another
possible mechanism is adoptive transfer of autoimmunity
resulting in CNS inflammation in the host.
Complete resolution of symptoms or significant improvement
was observed in 6 patients and partial improvement was
reported in another 4 patients (5–7, 14, 18, 19). Eight of
them had marginal or no improvement following treatment
and data were not available for 2 patients (5–8, 13, 16).
A range of therapies including corticosteroids, intravenous
immunoglobulin, therapeutic plasma exchange, mycophenolate,
tacrolimus, cyclosporine A, cyclophosphamide, rituximab, and
donor lymphocyte infusion had been used in these 20 patients
(Table 2). Interferon ß was used in both patients, whose
diagnoses were compatible with MS. Five patients, who were
treated with mycophenolate, tacrolimus or cyclosporine A,
had complete resolution of symptoms or partial improvement
following treatment. The size of the sample was too small
for any statistical analysis, but normal CSF constitutes or
absence of oligoclonal bands were appeared to be associated with
better prognosis. Complete resolution of symptoms or significant
clinical improvement was observed more frequently in those
patients who had later onset of neurological symptoms following
allogeneic HSCT (Table 2).
CONCLUSIONS
This case was noteworthy for two reasons. Firstly, the disease
course which resembled an “MS-like” relapsing remitting
encephalomyelitis although the exact etiology remained
unknown even after autopsy. In such a case full autopsy
examination may be helpful to confirm the absence of occult
malignancy and also to investigate whether the disease was
limited to the CNS tissue. Secondly, this case demonstrated
the feasibility of using “domino” autologous HSCT in patients
presenting with “MS-like” encephalomyelitis following allogeneic
HSCT, but further studies are required to evaluate its safety
and efficacy.
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